2018年4月18日，青煜医药2018年学ζ术系列讲座在创想园举办。我们非常荣幸地邀请了Alex Matter博士做』了题目为‘Personalized anticancer drug discovery & development in Asia’ 的学︾术讲座。
Dr Alex Matter is CEO of the Experimental Therapeutics Centre since April 2009 and since January 2012 CEO of the newly created D3 platform, A*STAR, Singapore. Previously, he had spent five and a half years as Director of the Novartis Institute for Tropical Diseases (NITD), from October 2003 to February 2009. Prior to this role, Dr. Matter was Global Head of Oncology Research for Novartis Pharmaceuticals Corporation. Dr. Matter played an important role in the success of several anticancer drugs, including Gleevec/Glivec? .